THX Pharma is publicly listed.

Our listing reflects a commitment to building sustainable growth grounded in high standards of transparency, governance, and responsibility.

 

It enables us to support our activities financially, advance treatments’ market launches, and strengthen visibility among all of its stakeholders. This listing is a key element for our ambition: driving innovation for the benefit of patients living with rare neurological diseases.